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The Editorial on the Research Topic
Third-Generation Neuroimaging: Translating Research into Clinical Utility
As yet, no reliable structural or functional brain marker has been univocally associated with any 
psychiatric disorder, and no clinical applications have been developed in psychiatric neuroimaging 
(1–4). There is thus urgent need of psychiatric imaging to move toward third-generation paradigms. 
First-generation psychiatric neuroimaging focused on simple structural brain alterations associated 
with the neurobiology of the illness. These early studies adopted imaging methods mainly includ-
ing computerized tomography (CT) to investigate brain size (5). Second-generation psychiatric 
neuroimaging studies benefited from more sophisticated techniques, which included structural 
techniques such as magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI), 
functional approaches such as task-related or resting-state functional magnetic resonance imag-
ing (fMRI), and electroencephalography (EEG) and neurochemical measurements like positron 
emission tomography (PET), magnetic resonance spectroscopy (MRS), and single-photon emission 
computed tomography (SPECT). However, by using these powerful non-invasive measurements, 
psychiatric imaging needs to move away from simple investigations of the neurobiology underling 
the early phases of psychiatric diseases in order to translate imaging findings into daily clinical 
routines, targeting clinical outcomes including transition, remission, and response to preventative 
treatment scenarios (1, 2, 6–11).
The aim of this research topic is to provide the field with an overview of current third-
generation neuroimaging approaches in translational psychiatry that is hoped to improve and 
create therapeutic options for psychiatric diseases. This Research Topic includes articles indicating 
the potential of specific network connectivity analyses for inferring on the pathophysiological 
mechanisms of schizophrenia (Silverstein et  al.), autism spectrum disorder (Crippa et  al.), or 
suicidal behavior (Serafini et al.), or how they may help to predict the cognitive enhancing effect 
of pharmacological agents across disorders (van Amelsvoort and Hernaus) or psychotherapeutic 
interventions in patients with ADHD (Bachmann et al.) and schizophrenia and comorbid substance 
misuse problems (Wojtalik et al.). However, one article also emphasizes the importance of further 
second-generation imaging to investigate specific symptoms in a systematic manner before third-
generation imaging can be informed (de Cates and Broome). Further contributions are suggesting 
advanced optical topography (Ho et al.), 18F-FDG PET (Kowoll et al.), or EEG microstates (Rieger 
et  al.) or beta oscillation analyses (Ghorashi and Spencer) as promising approaches to guide 
third-generation imaging across disorders (Ho et al.) or in schizophrenia [Ghorashi and Spencer; 
Rieger et al.], while others argue for the fusion of multimodal imaging modalities (Bellani et al.; 
Chiapponi et  al.; O’Halloran et  al.). Multimodal approaches, which integrate brain activation 
and connectivity patterns with metabolic measurements, are also proposed to gain a better 
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understanding of the neuropathology underlying basic symptom 
in psychosis (Schultze-Lutter et al.). The current Research Topic 
also reveals the clinical utility of machine learning methods 
using multimodal imaging data in identifying individuals at 
high risk for psychosis (Valli et  al.) and predicting outcomes 
across psychiatric populations (O’Halloran et al.; Schnack and 
Kahn), as well as of real-time fMRI (Dyck et  al.; Fovet et  al.; 
Gerin et  al.) in treating symptoms of PTSD (Gerin et  al.) and 
auditory–verbal hallucinations in schizophrenia (Dyck et  al.; 
Fovet et al.). Finally, this topic outlines a theoretical framework 
how Hierarchical Bayesian Models of functional neuroimaging 
data may help to establish diagnostic test in autism spectrum 
disorder (Haker et al.).
This issue is intended to provide a useful framework for fur-
ther third-generation imaging investigations aiming at predicting 
clinical outcomes, such as transition, remission, and treatment 
responses in early phases of different psychiatric diseases. These 
types of analyses might help to improve and develop novel 
therapeutic scenarios. We would like to thank all the authors and 
reviewers for their valuable contributions, as well as the Editorial 
Office for their help in the editing process.
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